Changes in Beneficial Ownership · 4
Monte Rosa Therapeutics, Inc.
GLUENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-07-01
- Issuer
- Monte Rosa Therapeutics, Inc.
- Issuer CIK
- 0001826457
- Trading symbol
- GLUE
Reporting owner 1
- Name
- Behbahani Ali
- Reporting owner CIK
- 0001613867
- Relationship
- Director
- Address
- 2855 SAND HILL ROAD, MENLO PARK, CA, 94025
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-07-01 | J · Form 4[F1] | 1,000,000 | D | 0.00 | 6,692,298 | I | See Note 2[F2] |
| Common Stock | 2026-07-01 | J · Form 4[F3] | 15,000 | A | 0.00 | 15,000 | I | See Note 4[F4] |
| Common Stock | 2026-07-01 | J · Form 4[F5] | 15,000 | D | 0.00 | 0 | I | See Note 4[F4] |
Table key
- J · Form 4
- Other acquisition or disposition; see explanation
- D
- Disposed
- I
- Indirect
- A
- Acquired
Footnotes
- F1
- New Enterprise Associates 17, L.P. ("NEA 17") made a pro rata distribution of 1,000,000 shares of Common Stock of the Issuer to its general partner and limited partners for no consideration on July 1, 2026.↩ 1
- F2
- The Reporting Person is a manager of NEA 17 GP, LLC ("NEA 17 GP"), which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of NEA 17, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.↩ 1
- F3
- NEA Partners 17 received 15,000 shares of Common Stock of the Issuer in the distribution made by NEA 17 on July 1, 2026.↩ 1
- F4
- The Reporting Person is a manager of NEA 17 GP, the sole general partner of NEA Partners 17, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest.↩ 1↩ 2
- F5
- NEA Partners 17 made a distribution of 15,000 shares of Common Stock of the Issuer for no consideration on July 1, 2026.↩ 1
Signature 1
- Signed
- /s/ Zachary Bambach, attorney-in-fact
- Date
- 2026-07-06
Company context
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.